Business Context and Reporting Period
This Form 8-K is a current report filed by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc.) on December 17, 2019. The filing addresses a material change in executive leadership under Item 5.02.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and contains no financial performance data.
Material Changes
- Resignation: Mani Mohindru, Chief Financial Officer (CFO) and Chief Strategy Officer, resigned effective December 20, 2019, to join a privately held company.
- Interim Appointment: Richard Makara, Vice President, Head of Accounting & Controller, assumed the roles of Principal Financial Officer and Principal Accounting Officer on an interim basis immediately following Dr. Mohindru's departure.
- Reason for Departure: The resignation is not due to any dispute or disagreement with the Company.
Outlook and Management Commentary
The Company has commenced a search for a permanent replacement for Dr. Mohindru. Mr. Makara, who has served the Company since October 2014 and is a certified public accountant, will lead finance operations until a successor is appointed. No specific guidance, risks, or contingencies regarding future financial performance are disclosed in this filing.
Investor Verification Checklist
- Verify the timeline for the permanent CFO search and appointment.
- Review subsequent filings for any changes in financial reporting or strategy resulting from the leadership transition.
- Confirm the Company's liquidity position in the most recent 10-Q or 10-K, as this 8-K does not contain financial data.